Member Info for euclid55

Coldplay, pleas let us know the reply you get back from them.

Not sure a good idea if plenty of s/holders start bombarding them for the same request - let them issue any news as & when it's due. The quieter the better - otherwise it will fall into the ramping / de-ramping camp this share - so will not do it much good

They will have to wait until Aptamer has further news on their Aptamers first - then hopefully more news on this will be released

Picked up another 15k

Intelligent lung ultrasound provides crucial support for COVID-19 testing within minutes

https://medicalxpress.com/news/2020-05-intelligent-lung-ultrasound-crucial-covid-.html

When Avct did their 2nd placing they never mentioned anything bout completing testing for Covid 19 - but I bet you they would if brought the places inside

https://www.investegate.co.uk/avacta-group-plc--avct-/rns/proposed-placing-to-raise--3-75-million/202004060700108126I/

Hillbilly1, please take some serious advice

If you just buy shares on getting sucked in you need to go back to your drawing board and complete exceptional and long detailed research on any company you invest in.

amazing the people that get complaining here - because they are simply short term gamblers

Re read all the reports on The Aptamer Group and corollate with what Paraytec systems can integrate with their Aptamers.

I am not complaining, even though I got 100,000 at 32p

Hello RollingInlt,

so you called the company and they confirmed that A Norris isn't privy to an II and did they confirm he is still selling - or are we all speculating it's him from the last TR1 rns?

I would of thought he would be made inside - but could be wrong

However, so long as talks are still ongoing with The Aptamer Group, that is still good news

Hi Torreaguas,

what info did you get back from co re RNS still the same - was it by p/call or an email to them please?

so assume that their Aptamer Platform agnostic will need UVI Imaging system tech to work best?

So hopefully the test that Aptamer group need for their technology fits into Paraytec's tech also - Abingdon Health works on medical tools - so they may play a part also

He says they are working with multiple end users - so maybe not just with Paraytec system

Just seen the url link on LinkedIn - thanks - I presume for any technical people out there that a platform agnostic system works with UVI imaging systems?

Do you have the URL link to the below you posted please?

Thanks
_ _ _____________________________

How crucial is Paraytec imaging technology for this project to be viable?

Can you produce a similar POC test that doesn't require Paraytec involvement, would this be cheaper?

His Answer: The aptamers we are developing are platform agnostic. We are working with multiple end users for access to the technology we are developing.

Hello TorreA

Your post below from Aptamer doesn't specifically say they have to use Paraytec's Imaging technology - is that how you read it ?

CompareHemo who raised £2.5m to advance their testing on mice - see extract rns below and they have a £37m market cap
They are several months away before they can even start to test this on humans - so in a way Aptamer Group are more nearer to developing something than Hemo and we are not testing into mice either. - so the derampes can think about that.

progress the Company's studies into the use of its advanced humanized mice for the potential development of human neutralizing antibodies to be used against COVID-19 and related COVID-19 work

https://www.investegate.co.uk/Index.aspx?searchtype=3&words=hemo

Nilsen-Hamilton envisions the production of small portable devices, about the size of a phone, that people can operate without having to go to a hospital or clinic. The devices require a blood or saliva sample, which the devices analyze and report the presence of viruses or viral antibodies. Nilsen-Hamilton said this technology would be inexpensive, portable and adaptable to a wide range of viruses.

Newswise — AMES, Iowa – Iowa State University scientists are working with a multi-institutional research group to develop an innovative viral testing platform that could function inexpensively in rural areas. The research has the potential to address the current pandemic and could make a big difference if similar viral outbreaks occur in the years ahead.

Marit Nilsen-Hamilton, a professor of biochemistry, biophysics and molecular biology, is the principal investigator for the research group, which includes experts in virology and engineering. The team is developing virus testing devices that could be used without the benefit of medical facilities, which would be particularly useful in rural or remote regions. The idea grew out of work Nilsen-Hamilton started through her company, Aptalogic, aimed at developing portable testing devices for the Ebola virus.

The concept depends on aptamers, which are nucleic acids that behave like antibodies in the human immune system. Aptamers can be selected in the laboratory to bind to the spike proteins of coronaviruses, creating a detection method that can be replicated and widely distributed because aptamers are more stable and more easily stored than human antibodies.

“We’re moving toward isolating an aptamer that would recognize the viral cause of COVID-19,” Nilsen-Hamilton said. “We had planned to do this research well before the pandemic, but now we’ve decided to put it on the front burner.”

Nilsen-Hamilton envisions the production of small portable devices, about the size of a phone, that people can operate without having to go to a hospital or clinic. The devices require a blood or saliva sample, which the devices analyze and report the presence of viruses or viral antibodies. Nilsen-Hamilton said this technology would be inexpensive, portable and adaptable to a wide range of viruses.

Https://www.newswise.com/coronavirus/scientists-developing-portable-viral-tests-for-future-pandemics/?article_id=730044

Viruses replicate inside the cells of an organism and continuously evolve to contend with an ever-changing environment. Many life-threatening diseases, such as AIDS, SARS, hepatitis and some cancers, are caused by viruses. Because viruses have small genome sizes and high mutability, there is currently a lack of and an urgent need for effective treatment for many viral pathogens.

One approach that has recently received much attention is aptamer-based therapeutics. Aptamer technology has high target specificity and versatility, i.e., any viral proteins could potentially be targeted. Consequently, new aptamer-based therapeutics have the potential to lead a revolution in the development of anti-infective drugs. Additionally, aptamers can potentially bind any targets and any pathogen that is theoretically amenable to rapid targeting, making aptamers invaluable tools for treating a wide range of diseases. This review will provide a broad, comprehensive overview of viral therapies that use aptamers.

The aptamer selection process will be described, followed by an explanation of the potential for treating virus infection by aptamers

A third advantage is that potent aptamers can be identified through the iterative SELEX process and evolved in a test tube within a month.

Moreover, large-scale manufacture of high quality current good manufacturing practice (cGMP)-grade nucleic acids is possible through solid-phase chemical synthesis, and aptamers, composed entirely of nucleic acids, are regarded as chemical drugs by FDA instead of biologics. These features all speed up the process of aptamer research and development.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873675/

Doubt they are the only co developing aptamers to be honest J Brown - looking at google there are plenty of co's in this sector of the market.

"Currently, there are fewer than 60 companies working with aptamers and fewer than 20 specialising in the custom development world-wide. DNA and RNA aptamers are more versatile than many currently available technologies: binding a wider range of targets, under a wider range of conditions at a cheaper relative price and, using our technology, they can be delivered more quickly than antibodies (6 to 12 weeks vs. 6 to 12 months). Aptamers and the technologies used to identify them are part of a rapidly growing global market,"

https://www.aptamergroup.co.uk/find-out-more/investors/

Another possibility is that of using aptamers against ACE-2 as inhibitory agents; this prospect is bolstered by the relatively fast development time available to aptamers through protein-based SELEX, which can reveal sequence candidates with high target specificity and sensitivity in a relatively short amount of time.

A further consideration is that aptamers conjugated to siRNAs or microRNAs (miRNAs) can be used to selectively target these antiviral agents to target cells and tissues, offering an avenue of delivery for silencing strategies previously outlined. Combining aptamers with antiviral oligos could be a powerful approach to therapeutic treatment and should be considered for CoV therapies.

The challenge will be delivery of the aptamers—those that are used therapeutically need to be injected by IV and are cleared rapidly. However, other forms of delivery offering superior pharmacokinetic profiles are being pursued, such as by our group's development of an aptamer suitable for subcutaneous administration.

https://www.liebertpub.com/doi/10.1089/NAT.2020.0868

University of Louisville researchers have developed a technology that is believed to block coronavirus SARS-CoV-2 from infecting human cells. Early tests show that this may stop viruses, from "hijacking" nucleolin to replicate inside the body. UofL is seeking to fast track development, including application to the Food and Drug Administration (FDA) for approval to start treating patients seriously affected with COVID-19.
The technology is based on a piece of synthetic DNA – an “aptamer” – which targets and binds with a human protein called nucleolin. Early tests show that this aptamer may stop viruses, including novel coronavirus, from “hijacking” nucleolin to replicate inside the body.

https://www.wtcky.org/2020/04/23/uofl-technology-shows-promise-fighting-coronavirus/

But he is constantly re repeating his posts - that's the problem - AVCT have other irons in the fire not just Covid 19 testing